Raul Altman

Summary

Country: Argentina

Publications

  1. ncbi Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 10:3. 2012
  2. ncbi Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina
    Thromb J 9:12. 2011
  3. ncbi The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina
    Thromb J 8:8. 2010
  4. ncbi Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 5:11. 2007
  5. ncbi Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation
    R Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    J Thromb Haemost 4:2022-7. 2006
  6. ncbi Does combined clopidogrel and statin therapy benefit patients with non-ST-elevation myocardial infarction?
    Raul Altman
    Faculty of Medicine, , Argentina
    Nat Clin Pract Cardiovasc Med 2:558-9. 2005
  7. ncbi Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor
    Raul Altman
    Centro de Trombosis de Buenos Aires, School of Medicine, University of Buenos Aires, Argentina
    Clin Appl Thromb Hemost 11:271-7. 2005
  8. ncbi Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study
    Raul Altman
    Centro de Trombosis de Buenos Aires, Catedra de Magister en Trombosis, Facultad de Medicina de Tucuman, Buenos Aires, Argentina
    Circulation 106:191-5. 2002
  9. ncbi No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease
    Raul Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Inflammation 26:25-30. 2002
  10. ncbi Effect of sodium arachidonate on thrombin generation through platelet activation--inhibitory effect of aspirin
    R Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Thromb Haemost 84:1109-12. 2000

Collaborators

Detail Information

Publications12

  1. ncbi Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 10:3. 2012
    ..abstract:..
  2. ncbi Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina
    Thromb J 9:12. 2011
    ....
  3. ncbi The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
    Raul Altman
    Centro de Trombosis de Buenos Aires, Viamonte 2008, 1056 Buenos Aires, Argentina
    Thromb J 8:8. 2010
    ..Since thrombin is the main hemostatic agent, this study investigated the effect of rFVIIa and tissue factor (TF) on thrombin generation (TG) in vitro...
  4. ncbi Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy
    Raul Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    Thromb J 5:11. 2007
    ..Although some preliminary data have been already published, to confirm the potential benefit of anti-inflammatory drugs in acute coronary syndromes large prospective double-bind randomized trials are necessary...
  5. ncbi Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation
    R Altman
    Centro de Trombosis de Buenos Aires, Buenos Aires, Argentina
    J Thromb Haemost 4:2022-7. 2006
    ..This study investigated: (a) whether a regimen of aspirin or clopidogrel plus aspirin significantly inhibited platelet thrombin generation (TG); and (b) the reversal of this inhibition by recombinant activated factor VII (rFVIIa)...
  6. ncbi Does combined clopidogrel and statin therapy benefit patients with non-ST-elevation myocardial infarction?
    Raul Altman
    Faculty of Medicine, , Argentina
    Nat Clin Pract Cardiovasc Med 2:558-9. 2005
  7. ncbi Abciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factor
    Raul Altman
    Centro de Trombosis de Buenos Aires, School of Medicine, University of Buenos Aires, Argentina
    Clin Appl Thromb Hemost 11:271-7. 2005
    ..Abciximab, which affects non-aspirinated, nonactivated PRP weakly, has no effect on AA or TF in activated control PRP or in vivo aspirinated PRP...
  8. ncbi Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study
    Raul Altman
    Centro de Trombosis de Buenos Aires, Catedra de Magister en Trombosis, Facultad de Medicina de Tucuman, Buenos Aires, Argentina
    Circulation 106:191-5. 2002
    ....
  9. ncbi No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease
    Raul Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Inflammation 26:25-30. 2002
    ..These results suggest that no causal association exists between inflammation and C. pneumoniae. A highly significant correlation between C-reactive protein and fibrinogen levels was found...
  10. ncbi Effect of sodium arachidonate on thrombin generation through platelet activation--inhibitory effect of aspirin
    R Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Thromb Haemost 84:1109-12. 2000
    ..Sodium arachidonate was used in this study to determine its capacity to generate thrombin through platelet activation. Whether aspirin prevent this effect was also investigated...
  11. ncbi Fibrinogen: intra-individual variability in patients with arterial disease and in patients with cardiac valve replacements
    Jorge Rouvier
    Buenos Aires Thrombosis Center, Buenos Aires, Argentina
    Isr Med Assoc J 4:992-5. 2002
    ..Elevated fibrinogen, considered an independent risk factor for coronary disease, stratifies an individual as high risk for coronary disease. A risk marker requires little intra-individual variability during a long period...
  12. ncbi Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor
    R Altman
    Centro de Trombosis de Buenos Aires, Argentina
    Haemostasis 28:229-35. 1998
    ..01). We concluded that at comparable therapeutic doses, subcutaneous UFHvar released more free TFPI than LMWH and ComHep. A synergism between LMWH and low dose of UFH was found in 4-, 6- and 12-hour blood samples...